Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia
It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the trea...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00897/full |
id |
doaj-cc40f00a8ca64b91b8a6a499e8a50730 |
---|---|
record_format |
Article |
spelling |
doaj-cc40f00a8ca64b91b8a6a499e8a507302020-11-24T22:58:34ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-12-01810.3389/fphar.2017.00897296857Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid LeukemiaHabsah Aziz0Chow Y. Ping1Hamidah Alias2Nurul-Syakima Ab Mutalib3Rahman Jamal4UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaUKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaDepartment of Paediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaUKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaUKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, MalaysiaIt is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases.http://journal.frontiersin.org/article/10.3389/fphar.2017.00897/fullacute myeloid leukemiamutationadultchildhoodrelapsebiomarker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Habsah Aziz Chow Y. Ping Hamidah Alias Nurul-Syakima Ab Mutalib Rahman Jamal |
spellingShingle |
Habsah Aziz Chow Y. Ping Hamidah Alias Nurul-Syakima Ab Mutalib Rahman Jamal Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia Frontiers in Pharmacology acute myeloid leukemia mutation adult childhood relapse biomarker |
author_facet |
Habsah Aziz Chow Y. Ping Hamidah Alias Nurul-Syakima Ab Mutalib Rahman Jamal |
author_sort |
Habsah Aziz |
title |
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
title_short |
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
title_full |
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
title_fullStr |
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
title_full_unstemmed |
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
title_sort |
gene mutations as emerging biomarkers and therapeutic targets for relapsed acute myeloid leukemia |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2017-12-01 |
description |
It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases. |
topic |
acute myeloid leukemia mutation adult childhood relapse biomarker |
url |
http://journal.frontiersin.org/article/10.3389/fphar.2017.00897/full |
work_keys_str_mv |
AT habsahaziz genemutationsasemergingbiomarkersandtherapeutictargetsforrelapsedacutemyeloidleukemia AT chowyping genemutationsasemergingbiomarkersandtherapeutictargetsforrelapsedacutemyeloidleukemia AT hamidahalias genemutationsasemergingbiomarkersandtherapeutictargetsforrelapsedacutemyeloidleukemia AT nurulsyakimaabmutalib genemutationsasemergingbiomarkersandtherapeutictargetsforrelapsedacutemyeloidleukemia AT rahmanjamal genemutationsasemergingbiomarkersandtherapeutictargetsforrelapsedacutemyeloidleukemia |
_version_ |
1725646807355097088 |